Physician profile
Michael Ross Laffer
NPI 1639153497
$7,235.63
in general payments reported to CMS, 2019-2025
37 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $667 · 2021: $928 · 2022: $1,300 · 2023: $995 · 2024: $993 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,246 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,246.26 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,494.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,564.22 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $829.40 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $433.37 | 2019-2025 | Dupixent |
| Genzyme Corporation | $363.42 | 2022-2025 | |
| Circassia INC. | $184.37 | 2019-2020 | |
| Philips North America LLC | $138.73 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Amgen INC. | $114.59 | 2019-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $88.18 | 2022-2025 | Glassia |
| Inogen, INC. | $83.70 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen |
| Grifols USA, LLC | $82.30 | 2020-2024 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $78.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $67.15 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $66.63 | 2023-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $64.68 | 2023-2025 | Keytruda, Winrevair |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $63.84 | 2023-2024 | Inspire |
| Mylan Specialty L.P. | $62.99 | 2019-2024 | Yupelri |
| Pulmonx Corporation | $54.49 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mallinckrodt Hospital Products INC. | $48.99 | 2024-2025 | Acthar |
| Pfizer INC. | $34.02 | 2021-2025 | |
| Edwards Lifesciences Corporation | $29.97 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $29.04 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Resmed Corp | $24.97 | 2019 | |
| Axsome Therapeutics, INC. | $21.98 | 2023 | Sunosi |
| Alexion Pharmaceuticals, INC. | $20.51 | 2025 | Strensiq |
| Viatris Specialty LLC | $20.06 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $19.39 | 2025 | Lumryz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.06 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.30 | 2025 | Voquezna |
| Boston Scientific Corporation | $15.77 | 2022 | |
| Shire North American Group INC | $15.65 | 2019 | |
| Advanced Respiratory, INC | $15.08 | 2019 | |
| Exact Sciences Corporation | $14.90 | 2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $14.68 | 2019 | |
| Insmed, INC. | $14.64 | 2021 | |
| Verona Pharma, INC. | $14.19 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Laffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.